Prolor Biotech Takes Option to Peptide Rx Candidates from Weizmann's Yeda R&D | GenomeWeb

Israel's Prolor Biotech said recently that it has inked an evaluation and option agreement with Yeda Research and Development, the tech-transfer arm of the Weizmann Institute of Science.

Under the agreement, Prolor, located in the Weizmann Science Park in Nes-Ziona, has the option to obtain from Yeda a license to develop a number of peptide drug candidates, including an anti-obesity peptide, using a delivery technology developed at the Weizmann Institute.

Additional details of the agreement were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: gene flow between ancient chimpanzees and bonobos, and more.

A startup wants to match customers to wine based on their DNA and one critic calls the idea 'silly,' Stat News reports.

Researchers trace the origins of brown rats using genetic analysis to China, the New York Times reports.

In Nature this week: genetic history of HIV in the US, and more.